Purchase this article with an account.
Michel J. Belliveau, Marwan Abouammoh, David R. Almeida, Sanjay Sharma, Jeffrey Gale; Ranibizumab for Idiopathic Epiretinal Membranes: a Prospective Evaluation. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5193.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study the effect of ranibizumab on idiopathic epiretinal membranes (ERM).
Consecutive patients with idiopathic ERM were offered a series of intravitreal ranibizumab injections. Patients received three to six 0.05mg/0.1ml injections at monthly intervals. The primary outcome measure was central macular thickness (CMT) measured by spectral-domain OCT. Change in best-corrected visual acuity (VA) was assessed at distance and near.
Eleven patients (age 58-81, mean 70.6) were followed for 7 months with at least 1month follow-up after the final injection. There was a statistically significant but clinically insignificant reduction in CMT (mean difference 8 microns, 95% CI 0.06-16.12 p=0.049). ETDRS VA showed a mean gain of only 3 letters (p=0.083), and near VA showed a statistically significant improvement (mean logMAR from 0.25 to 0.16, p=0.001). There were no complications.
Despite the presence of vascular endothelial growth factor and receptors for this molecule in idiopathic ERM, a series of 3-6 monthly injections of ranibizumab does not appear to have an effect as a sole treatment.
Clinical Trial: :
This PDF is available to Subscribers Only